|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rawla P, Sunkara T and Gaduputi V:
Epidemiology of pancreatic cancer: Global trends, etiology and risk
factors. World J Oncol. 10:10–27. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Adamska A, Domenichini A and Falasca M:
Pancreatic ductal adenocarcinoma: Current and evolving therapies.
Int J Mol Sci. 18:13382017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gillen S, Schuster T, Meyer Zum
Büschenfelde C, Friess H and Kleeff J: Preoperative/neoadjuvant
therapy in pancreatic cancer: A systematic review and meta-analysis
of response and resection percentages. PLoS Med. 7:e10002672010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maitra A and Hruban RH: Pancreatic cancer.
Annu Rev Pathol. 3:157–188. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Siegel RL, Fedewa SA, Miller KD,
Goding-Sauer A, Pinheiro PS, Martinez-Tyson D and Jemal A: Cancer
statistics for hispanics/latinos, 2015. CA Cancer J Clin.
65:457–480. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McGuigan A, Kelly P, Turkington RC, Jones
C, Coleman HG and McCain RS: Pancreatic cancer: A review of
clinical diagnosis, epidemiology, treatment and outcomes. World J
Gastroenterol. 24:4846–4861. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garrido-Laguna I and Hidalgo M: Pancreatic
cancer: From state-of-the-art treatments to promising novel
therapies. Nat Rev Clin Oncol. 12:319–324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Neoptolemos JP, Stocken DD, Friess H,
Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C,
Lacaine F, et al: A randomized trial of chemoradiotherapy and
chemotherapy after resection of pancreatic cancer. N Engl J Med.
350:1200–1210. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Amrutkar M and Gladhaug IP: Pancreatic
cancer chemoresistance to gemcitabine. Cancers (Basel). 9:1572017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li H, Jiang JD and Peng ZG:
MicroRNA-mediated interactions between host and hepatitis C virus.
World J Gastroenterol. 22:1487–1496. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Macfarlane LA and Murphy PR: MicroRNA:
Biogenesis, function and role in cancer. Curr Genomics. 11:537–561.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen X, Cheng JY and Yin J: Predicting
microRNA-disease associations using bipartite local models and
hubness-aware regression. RNA Biol. 15:1192–1205. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hatziapostolou M, Polytarchou C and
Iliopoulos D: miRNAs link metabolic reprogramming to oncogenesis.
Trends Endocrinol Metab. 24:361–373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dillhoff M, Liu J, Frankel W, Croce C and
Bloomston M: MicroRNA-21 is overexpressed in pancreatic cancer and
a potential predictor of survival. J Gastrointest Surg.
12:2171–2176. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Szafranska AE, Davison TS, John J, Cannon
T, Sipos B, Maghnouj A, Labourier E and Hahn SA: MicroRNA
expression alterations are linked to tumorigenesis and
non-neoplastic processes in pancreatic ductal adenocarcinoma.
Oncogene. 26:4442–4452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marzoq AJ, Giese N, Hoheisel JD and
Alhamdani MSS: Proteome variations in pancreatic stellate cells
upon stimulation with proinflammatory factors. J Biol Chem.
288:32517–32527. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakai S, Iwata C, Tanaka HY, Cabral H,
Morishita Y, Miyazono K and Kano MR: Increased fibrosis and
impaired intratumoral accumulation of macromolecules in a murine
model of pancreatic cancer co-administered with FGF-2. J Control
Release. 230:109–115. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shen J, Zhang J, Xiao M, Yang J and Zhang
N: miR-203 suppresses bladder cancer cell growth and targets
twist1. Oncol Res. 26:1155–1165. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chi Y, Jin Q, Liu X, Xu L, He X, Shen Y,
Zhou Q, Zhang J and Jin M: miR-203 inhibits cell proliferation,
invasion, and migration of non-small-cell lung cancer by
downregulating RGS17. Cancer Sci. 108:2366–2372. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zierau O, Helle J, Schadyew S, Morgenroth
Y, Bentler M, Hennig A, Chittur S, Tenniswood M and Kretzschmar G:
Role of miR-203 in estrogen receptor-mediated signaling in the rat
uterus and endometrial carcinoma. J Cell Biochem. 119:5359–5372.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Du SL, Xu LY, Gao P, Liu QS, Lu FF, Mo ZH,
Fan ZZ, Cheng XL and Dong ZH: miR-203 regulates DJ-1 expression and
affects proliferation, apoptosis and DDP resistance of pancreatic
cancer cells. Eur Rev Med Pharmacol Sci. 23:8833–8840.
2019.PubMed/NCBI
|
|
25
|
Lin XM, Chen H and Zhan XL: miR-203
regulates JAK-STAT pathway in affecting pancreatic cancer cells
proliferation and apoptosis by targeting SOCS3. Eur Rev Med
Pharmacol Sci. 23:6906–6913. 2019.PubMed/NCBI
|
|
26
|
Greither T, Grochola LF, Udelnow A,
Lautenschläger C, Würl P and Taubert H: Elevated expression of
microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated
with poorer survival. Int J Cancer. 126:73–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He S, Zhang G, Dong H, Ma M and Sun Q:
miR-203 facilitates tumor growth and metastasis by targeting
fibroblast growth factor 2 in breast cancer. Onco Targets Ther.
9:6203–6210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu M, Gu M, Zhang K, Zhou J, Wang Z and Da
J: miR-203 inhibition of renal cancer cell proliferation, migration
and invasion by targeting of FGF2. Diagn Pathol. 10:242015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fu XF, Tian YZ and Dong XS: Effects of
gemcitabine combined with heparanase inhibitor on invasion and
migration of pancreatic cancer PANC-1 cells. Chin Med Clin.
15:20–22. 2015.
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dąbkowski K, Bogacka B, Tarnowski M and
Starzyńska T: Pancreatic cancer microenvironment. Pol Merkur
Lekarski. 41:296–302. 2016.(In Polish).
|
|
32
|
Coleman SJ, Chioni AM, Ghallab M, Anderson
RK, Lemoine NR, Kocher HM and Grose RP: Nuclear translocation of
FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic
cancer cell invasion. EMBO Mol Med. 6:467–481. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mardhian DF, Vrynas A, Storm G, Bansal R
and Prakash J: FGF2 engineered SPIONs attenuate tumor stroma and
potentiate the effect of chemotherapy in 3D heterospheroidal model
of pancreatic tumor. Nanotheranostics. 4:26–39. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ren B, Cui M, Yang G, Wang H, Feng M, You
L and Zhao Y: Tumor microenvironment participates in metastasis of
pancreatic cancer. Mol Cancer. 17:1082018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fu XF, Dong XS, Gao F and Zhao HC: The
expression of fibroblast grouth factor 2 in pancreatic cancer and
its effect and mechanism on the invasion and metastasis of
pancreatic cancer cells. J Shanxi Med Univ. 87:26–31. 2017.
|
|
36
|
Kostas M, Lampart A, Bober J, Wiedlocha A,
Tomala J, Krowarsch D, Otlewski J and Zakrzewska M: Translocation
of exogenous FGF1 and FGF2 protects the cell against apoptosis
independently of receptor activation. J Mol Biol. 430:4087–4101.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shirakihara T, Horiguchi K, Miyazawa K,
Ehata S, Shibata T, Morita I, Miyazono K and Saitoh M: TGF-β
regulates isoform switching of FGF receptors and
epithelial-mesenchymal transition. EMBO J. 30:783–795. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen X and Zhao H, Chen C, Li J, He J, Fu
X and Zhao H: The HPA/SDC1 axis promotes invasion and metastasis of
pancreatic cancer cells by activating EMT via FGF2 upregulation.
Oncol Lett. 19:211–220. 2020.PubMed/NCBI
|
|
39
|
Wang N, Zheng J, Chen Z, Liu Y, Dura B,
Kwak M, Xavier-Ferrucio J, Lu YC, Zhang M, Roden C, et al:
Single-cell microRNA-mRNA co-sequencing reveals non-genetic
heterogeneity and mechanisms of microRNA regulation. Nat Commun.
10:952019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tan S, Xia L, Yi P, Han Y, Tang L, Pan Q,
Tian Y, Rao S, Oyang L, Liang J, et al: Exosomal miRNAs in tumor
microenvironment. J Exp Clin Cancer Res. 39:672020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Parente P, Parcesepe P, Covelli C,
Olivieri N, Remo A, Pancione M, Latiano TP, Graziano P, Maiello E
and Giordano G: Crosstalk between the tumor microenvironment and
immune system in pancreatic ductal adenocarcinoma: Potential
targets for new therapeutic approaches. Gastroenterol Res Pract.
2018:75306192018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee M and Rhee I: Cytokine signaling in
tumor progression. Immune Netw. 17:214–227. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Akl MR, Nagpal P, Ayoub NM, Tai B, Prabhu
SA, Capac CM, Gliksman M, Goy A and Suh KS: Molecular and clinical
significance of fibroblast growth factor 2 (FGF2 /bFGF) in
malignancies of solid and hematological cancers for personalized
therapies. Oncotarget. 7:44735–44762. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shi K, Qiu X, Zheng W, Yan D and Peng W:
miR-203 regulates keloid fibroblast proliferation, invasion, and
extracellular matrix expression by targeting EGR1 and FGF2. Biomed
Pharmacother. 108:1282–1288. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li B, Pi Z, Liu L, Zhang B, Huang X, Hu P,
Chevet E, Yi P and Liu J: FGF-2 prevents cancer cells from ER
stress-mediated apoptosis via enhancing proteasome-mediated Nck
degradation. Biochem J. 452:139–145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Turner N and Grose R: Fibroblast growth
factor signalling: From development to cancer. Nat Rev Cancer.
10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mohammadi M, Olsen SK and Ibrahimi OA:
Structural basis for fibroblast growth factor receptor activation.
Cytokine Growth Factor Rev. 16:107–137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li J, Shan F, Xiong G, Chen X, Guan X,
Wang JM, Wang WL, Xu X and Bai Y: EGF-induced C/EBPβ participates
in EMT by decreasing the expression of miR-203 in esophageal
squamous cell carcinoma cells. J Cell Sci. 127:3735–3744.
2014.PubMed/NCBI
|
|
49
|
Zhang K, Dai L, Zhang B, Xu X, Shi J, Fu
L, Chen X, Li J and Bai Y: miR-203 is a direct transcriptional
target of E2F1 and causes G1 arrest in esophageal cancer cells. J
Cell Physiol. 230:903–910. 2015. View Article : Google Scholar : PubMed/NCBI
|
